Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Anticancer Research|March 10, 2015
Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancerKimio Yonesaka, Taroh Satoh, Shinya Ueda, et al.
International Journal of Cancer|July 6, 2017
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistanceNaoki Takegawa, Yoshikane Nonagase, Kimio Yonesaka, et al.
Oncogenesis|October 2, 2019
Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKIKimio Yonesaka, Kaoru Tanaka, Mutsukazu Kitano, et al.
British Journal of Cancer|December 10, 2020
Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblastsRyoji Kato, Koji Haratani, Hidetoshi Hayashi, et al.
JAMA Oncology|October 5, 2017
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung CancerKoji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, et al.
Esophagus : Official Journal of the Japan Esophageal Society|December 9, 2022
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinomaSeiichiro Mitani, Hisato Kawakami, Osamu Shiraishi, et al.
International Journal of Cancer|May 16, 2019
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplificationNaoki Takegawa, Junji Tsurutani, Hisato Kawakami, et al.
Cancer Medicine|February 1, 2019
Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancerSatomi Watanabe, Kimio Yonesaka, Junko Tanizaki, et al.
Oncotarget|December 5, 2014
The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cellsHisato Kawakami, Isamu Okamoto, Kimio Yonesaka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancersKimio Yonesaka, Kreshnik Zejnullahu, Neal Lindeman, et al.
Pageof 7